Contraindications
- Severe ketosis, diabetic coma or precoma, type 1 diabetes
- Severe infection, around surgery, serious trauma
- Hypersensitivity
Dosing: Adult
- Type 2 diabetes: 20 mg once daily; may increase to 40 mg once daily with close monitoring if response is inadequate
Dosing: Altered kidney function
Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor cleared by both liver (CYP3A4, flavin monooxygenases) and kidney (15% to 22% unchanged in urine). Kidney impairment raises exposure only modestly (at most about 1.7-fold), and the Thai label, based on the Japanese originator, sets no kidney dose adjustment; hemodialysis removes about 16% of a dose. It has no US FDA label.
Kidney function measure: The label reports kidney pharmacokinetics by severity without numeric thresholds or dose changes; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 20 mg once daily; may increase to 40 mg once daily with close monitoring (Thai SmPC).
- CrCl 30–59 mL/min
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- CrCl 15–29 mL/min
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- CrCl <15 mL/min (not on dialysis)
- The label gives no kidney dose change; exposure (AUC) was about 1.25-, 1.68- and 1.49-fold higher in mild, moderate and severe impairment (Thai SmPC). A dedicated PK study found no need for adjustment through end-stage kidney disease (Halabi 2013). The 40 mg dose was not studied in kidney impairment; increase only with close monitoring.
- Hemodialysis (intermittent)
- No dose change in the label; end-stage kidney failure AUC about 1.16-fold; hemodialysis removed 15.6% of the dose (Thai SmPC). Dialysis timing not critical.
- Peritoneal dialysis
- No PD data; no change expected from end-stage kidney failure data (AUC about 1.16-fold).
- CRRT
- No data. Insulin is usual in critical illness.
- Dialyzable? Partly: hemodialysis removed 15.6% of the dose (Thai SmPC).
- Monitoring Hypoglycemia with a sulfonylurea or insulin (lower their dose). Avoid with QT prolongation or torsades history; caution with class IA or III antiarrhythmics. Persistent severe abdominal pain (pancreatitis), intestinal obstruction in those with prior abdominal surgery (Thai SmPC). Caution in severe hepatic impairment (no experience). In dialysis patients, check QTc and electrolytes when other QT risk factors are present.
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: Thai FDA product information (September 2021). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not established in children.
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 20 mg, 20 mg/15 mg
Registered products in the Philippines
8 products registered with the Food and Drug Administration (FDA) Philippines list Teneligliptin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Teneligliptin (as Hemipentahydrobromide hydrate) Tenglyn (1 product). Products registered under these spellings are included in the table and marked.
All registered products8
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DigliptinTeneligliptin (as hydrobromide hydrate) | 20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Baroque Pharmaceuticals Pvt. Ltd.India | Amb Hk Enterprises Inc. | DRP-16680 | Jun 5, 2030 | |
GliptenTeneligliptin (as Hydrobromide Hydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY45743 | Jan 12, 2027 | |
Glypsa 20Teneligliptin (as hydrobromide hydrate) | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | Saifen Drugs Philippines Inc. | DRP-16035 | Oct 18, 2029 | |
TenelizoneTeneligliptin (as hydrobromide hydrate + Pioglitazone (Hydrochloride) | 20mg/ 15mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47500 | Nov 19, 2026 | |
TenemaxTeneligliptin (as hydrobromide hydrate) | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | The Cathay Yss Distributors Co., Inc. | DR-XY47994 | May 2, 2027 | |
TenemedTeneligliptin | 20 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | Medinova Pharmaceutical Inc. | DR-XY49536 | Oct 7, 2030 | |
Tenepride-20Teneligliptin (as hydrobromide hydrate) | 20 mg Film Coated tabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Importer: Brown & Burk Phils., Inc. | DR-XY48005 | May 6, 2027 | |
20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | Rx | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DR-XY47979 | Apr 28, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Class IA (quinidine, procainamide) and class III (amiodarone, sotalol) antiarrhythmics | Adjust or monitor | Additive QT prolongation. | Use with caution; avoid in QT prolongation. |
| Sulfonylureas, insulin | Adjust or monitor | More hypoglycemia. | Consider lowering their dose. |
| Ketoconazole (strong CYP3A4 inhibitor) | Minor | Teneligliptin AUC up about 1.49-fold. | Monitor. |
| Beta-blockers, salicylates, MAO inhibitors; corticosteroids, thyroid hormone, epinephrine | Minor | Increase or reduce glucose lowering. | Monitor glucose. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Hypoglycemia (2.6%)
- Constipation (0.9%)
Serious
- Hypoglycemia (with sulfonylurea or insulin)
- Intestinal obstruction (0.1%)
- Acute pancreatitis
- Hepatic dysfunction
- Interstitial pneumonia
- Bullous pemphigoid
- QT prolongation
Monitoring parameters
- Hypoglycemia with a sulfonylurea or insulin (lower their dose). Avoid with QT prolongation or torsades history; caution with class IA or III antiarrhythmics. Persistent severe abdominal pain (pancreatitis), intestinal obstruction in those with prior abdominal surgery (Thai SmPC). Caution in severe hepatic impairment (no experience). In dialysis patients, check QTc and electrolytes when other QT risk factors are present. Kidney
- Glucose and HbA1c
- ECG in patients with QT risk
Pharmacokinetics
Key PK parameters
| Time to peak | Delayed by food (AUC unchanged) |
|---|---|
| Half-life | About 24 hours (single dose); about 30 hours after 7 days |
| Half-life in kidney failure (ESKD) kidney | AUC up to about 1.68-fold (moderate impairment); 1.16-fold in end-stage kidney failure |
| Protein binding | About 78% to 82% |
| Metabolism (CYP, transporters) | CYP3A4 and flavin-containing monooxygenases (FMO1, FMO3) |
| Renal excretion kidney | 14.8% to 22.1% unchanged in urine |
| Dialyzability kidney | 15.6% removed by hemodialysis |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Thai Food and Drug Administration. Tenelia 20 mg tablets SmPC (1C 15074/63 (NC)) [Thai FDA product information, September 2021; no US FDA label]. https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/3b192a1e00da902ea978f0b2304c6b9c-a1.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Mitsubishi Tanabe Pharma (Thailand). (2021). Tenelia 20 mg tablets (teneligliptin hydrobromide hydrate) [Summary of product characteristics, authorization 1C 15074/63 (NC); text revised September 2021]. Thai Food and Drug Administration. https://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/1163/3b192a1e00da902ea978f0b2304c6b9c-a1.pdf
- Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., Lufft, V., & Klause, N. (2013). Pharmacokinetics of teneligliptin in subjects with renal impairment. Clinical Pharmacology in Drug Development, 2(3), 246–254. https://doi.org/10.1002/cpdd.29
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .